Cargando…
S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428495/ http://dx.doi.org/10.1097/01.HS9.0000967448.25247.8c |
| _version_ | 1785090483785039872 |
|---|---|
| author | Russell, Nigel Othman, Jad Dillon, Richard Potter, Nicola Wilhelm-Benartzi, Charlotte Knapper, Steven Batten, Leona Canham, Joanna Hinson, Emily Laura Malthe Overgaard, Ulrik Gilkes, Amanda Mehta, Priyanka Kottaridis, Panagiotis Cavenagh, Jamie Hemmaway, Claire Arnold, Claire Freeman, Sylvie Dennis, Mike |
| author_facet | Russell, Nigel Othman, Jad Dillon, Richard Potter, Nicola Wilhelm-Benartzi, Charlotte Knapper, Steven Batten, Leona Canham, Joanna Hinson, Emily Laura Malthe Overgaard, Ulrik Gilkes, Amanda Mehta, Priyanka Kottaridis, Panagiotis Cavenagh, Jamie Hemmaway, Claire Arnold, Claire Freeman, Sylvie Dennis, Mike |
| author_sort | Russell, Nigel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428495 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284952023-08-17 S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL Russell, Nigel Othman, Jad Dillon, Richard Potter, Nicola Wilhelm-Benartzi, Charlotte Knapper, Steven Batten, Leona Canham, Joanna Hinson, Emily Laura Malthe Overgaard, Ulrik Gilkes, Amanda Mehta, Priyanka Kottaridis, Panagiotis Cavenagh, Jamie Hemmaway, Claire Arnold, Claire Freeman, Sylvie Dennis, Mike Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428495/ http://dx.doi.org/10.1097/01.HS9.0000967448.25247.8c Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Russell, Nigel Othman, Jad Dillon, Richard Potter, Nicola Wilhelm-Benartzi, Charlotte Knapper, Steven Batten, Leona Canham, Joanna Hinson, Emily Laura Malthe Overgaard, Ulrik Gilkes, Amanda Mehta, Priyanka Kottaridis, Panagiotis Cavenagh, Jamie Hemmaway, Claire Arnold, Claire Freeman, Sylvie Dennis, Mike S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title | S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title_full | S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title_fullStr | S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title_full_unstemmed | S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title_short | S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL |
| title_sort | s134: flag-ida combined with gemtuzumab ozogamicin (go) reduced mrd levels and improved overall survival in npm1mut aml independent of flt3 and mrd status, results from the aml19 trial |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428495/ http://dx.doi.org/10.1097/01.HS9.0000967448.25247.8c |
| work_keys_str_mv | AT russellnigel s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT othmanjad s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT dillonrichard s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT potternicola s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT wilhelmbenartzicharlotte s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT knappersteven s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT battenleona s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT canhamjoanna s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT hinsonemilylaura s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT maltheovergaardulrik s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT gilkesamanda s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT mehtapriyanka s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT kottaridispanagiotis s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT cavenaghjamie s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT hemmawayclaire s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT arnoldclaire s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT freemansylvie s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial AT dennismike s134flagidacombinedwithgemtuzumabozogamicingoreducedmrdlevelsandimprovedoverallsurvivalinnpm1mutamlindependentofflt3andmrdstatusresultsfromtheaml19trial |